Daxor (NASDAQ:DXR) versus Nyxoah (NASDAQ:NYXH) Head-To-Head Review

Daxor (NASDAQ:DXR) and Nyxoah (NASDAQ:NYXH) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, earnings, analyst recommendations, valuation and profitability.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Daxor and Nyxoah, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Daxor	0	0	0	0	N/A
Nyxoah	0	1	5	0	2.83

Nyxoah has a consensus price target of $20.20, indicating a potential upside of 99.60%. Given Nyxoah’s higher possible upside, analysts plainly believe Nyxoah is more favorable than Daxor.

Insider & Institutional Ownership

1.3% of Daxor shares are held by institutional investors. 60.6% of Daxor shares are held by company insiders. Comparatively, 17.1% of Nyxoah shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Daxor and Nyxoah’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Daxor	N/A	N/A	N/A	N/A	N/A
Nyxoah	$4.70 million	N/A	-$46.77 million	($1.68)	-6.02

Daxor has higher earnings, but lower revenue than Nyxoah.

Volatility & Risk

Daxor has a beta of -0.45, suggesting that its share price is 145% less volatile than the S&P 500. Comparatively, Nyxoah has a beta of 1.58, suggesting that its share price is 58% more volatile than the S&P 500.

Profitability

This table compares Daxor and Nyxoah’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Daxor	N/A	N/A	N/A
Nyxoah	-843.48%	-42.14%	-33.55%

Summary

Daxor beats Nyxoah on 5 of the 9 factors compared between the two stocks.

About Daxor

Daxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee.

About Nyxoah

Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.